Chee Ning WongKai Bin Liew0000-0003-1377-7655Lim Yang MooiYik-Ling ChewAng-Lim ChuaShi-Bing Yang0000-0001-9299-6842Siew-Keah LEE2026-11-102026-11-102025-11-0710.3390/pharmaceutics17111441https://dspace-cris.utar.edu.my/handle/123456789/11869Background: Epigallocatechin-3-gallate (EGCG), a potent green tea polyphenol, possesses significant therapeutic potential, but its clinical application is limited by poor gastrointestinal stability and low oral bioavailability. To address this, a novel herbal nanomedicine-based delivery system was developed utilizing D-?-tocopheryl polyethylene glycol succinate (TPGS) and Poloxamer 407. Objectives: This study aims to develop and characterize EGCG-loaded TPGS/Poloxamer 407 micelles, evaluating their physicochemical properties, storage stability, in vitro drug release profile, in vivo oral bioavailability, and preliminary tolerability observation. Methods: The micelles were prepared using the film hydration method followed by lyophilization. Results: The optimized 2:2 TPGS-to-poloxamer 407 weight ratio yielded EGCG-loaded micelles, displaying a mean particle size of 15.4 nm, a polydispersity index (PDI) of 0.16, a zeta potential of ?17.7 mV, an encapsulation efficiency of 82.7%, and a drug loading capacity of 7.6%. The critical micelle concentration (CMC) was determined to be 0.00125% w/v. Transmission electron microscopy (TEM) confirmed the micelles’ uniform spherical morphology. In vitro release studies demonstrated a sustained release profile in both simulated gastric and intestinal fluids. EGCG formulation remained stable for at least six months when stored at 4 °C. No adverse clinical signs were noted during the 28-day tolerability observation. In vivo pharmacokinetic evaluation in mice revealed a significant elevation in oral bioavailability, achieving a 2.27-fold increase in area under the curve (AUC) and a 1.8-fold increase in peak plasma concentration (Cmax) compared to free EGCG. Conclusions: Collectively, these findings underscore the potential of the TPGS/poloxamer 407-based micelle system as a promising oral delivery platform for EGCG, enhancing its stability and pharmacokinetic performance. © 2025 by the authors.en-USdrug releaseEGCGmicellepharmacokineticsphytochemical-based nanomedicinepoloxamerTPGScatechinacetic acid ethyl esteralanine aminotransferasealkaneascorbic acidaspartate aminotransferasecreatinined alpha tocopheryl polyethylene glycol succinatedistilled waterepigallocatechin gallatehydroxyl groupiodinemacrogol derivativepotassium iodideunclassified drugureaanimal experimentanimal modelanimal tissuearea under the curveArticleattenuated total reflectance Fourier transform infrared spectroscopybiochemical analysisbiocompatibilityblood samplingcontrolled studycritical micelle concentrationcryopreservationdialysisdispersitydrug analysisdrug bioavailabilitydrug delivery systemdrug developmentdrug eliminationdrug formulationdrug half lifedrug safetydrug stabilitydrug tolerabilitydrug toxicityencapsulationenzymatic degradationFourier transform infrared spectroscopyfreeze dryingheatinghydrationin vitro studyin vivo studyintestine fluidmalemass spectrometrymaximum plasma concentrationmousenonhumanparticle sizephoton correlation spectroscopyphysical chemistryplasma concentration-time curvesimulationstatic electricitystomach juicetemperaturethermodynamicstransmission electron microscopyultra performance liquid chromatographyX ray diffractionzeta potentialDevelopment and Characterization of EGCG-Loaded TPGS/Poloxamer 407 Micelles with Evaluation of In Vitro Drug Release and In Vivo Pharmacokinetics and Tolerability Observations Following Oral Administrationjournal-article